What type of study is this?

Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas

View Full Paper

Ask AI

Bookmark

CLDN18.2 positivity was observed in 48% of tumors, suggesting its role as a crucial biomarker.
Inclusion of CLDN18.2 increased actionable biomarker proportion to 92%, demonstrating its clinical relevance.
The study analyzed 145 cases from 2023 to 2024, highlighting the significance of identifying biomarkers.
Despite low intratumoral heterogeneity, 28% of tumors showed heterogeneous expression, indicating potential misclassification.

No takes yet. Share an insight, caveat, or question.

Study details coexpression of claudin 18.2 and other biomarkers in gastric cancers, indicating clarity on treatment options.

Liu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark